(Q43648622)

25 November 2017

title

A β-mannan trisaccharide conjugate vaccine aids clearance of Candida albicans in immunocompromised rabbits (English)

1 reference

25 November 2017

1 reference

Tomasz Lipinski

1

1 reference

25 November 2017

Xiangyang Wu

2

1 reference

25 November 2017

Joanna Sadowska

3

1 reference

25 November 2017

Erin Kreiter

4

1 reference

25 November 2017

Yutaka Yasui

5

1 reference

25 November 2017

Shilton Cheriaparambil

6

1 reference

25 November 2017

Robert Rennie

7

1 reference

25 November 2017

David R Bundle

8

1 reference

25 November 2017

language of work or name

English

0 references

publication date

14 August 2012

1 reference

25 November 2017

1 reference

25 November 2017

volume

30

1 reference

25 November 2017

issue

44

1 reference

25 November 2017

page(s)

6263-6269

1 reference

Nosocomial bloodstream infections in United States hospitals: a three-year analysis

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Risk factors for hospital-acquired candidemia. A matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Attributable mortality of nosocomial candidemia, revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Polysaccharide-containing conjugate vaccines for fungal diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Advances in combating fungal diseases: vaccines on the threshold

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

A novel glyco-conjugate vaccine against fungal pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Candidemia in a Canadian tertiary care hospital from 1976 to 1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Trends and sources of nosocomial fungaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Hepatic candidiasis in cancer patients: the evolving picture of the syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Antibodies against Candida: potential therapeutics?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Beta-glucan-CRM197 conjugates as candidates antifungal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Epidemiology of vaginitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Recurrent vulvovaginal candidiasis - allergy or immune deficiency?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Immunopathogenesis of recurrent vulvovaginal candidiasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Defining criteria for anti-mannan antibodies to protect against candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Structural study of cell wall phosphomannan of Candida albicans NIH B-792 (serotype B) strain, with special reference to 1H and 13C NMR analyses of acid-labile oligomannosyl residues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Existence of branched side chains in the cell wall mannan of pathogenic yeast, Candida albicans. Structure-antigenicity relationship between the cell wall mannans of Candida albicans and Candida parapsilosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

The unique solution structure and immunochemistry of the Candida albicans beta -1,2-mannopyranan cell wall antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Molecular recognition of Candida albicans (1->2)-β-mannan oligosaccharides by a protective monoclonal antibody reveals the immunodominance of internal saccharide residues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Synthesis of glycoconjugate vaccines for Candida albicans using novel linker methodology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

Variable expression of a surface determinant during proliferation of Candida albicans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

inferred from DOI database lookup

7 January 2021

based on heuristic

A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.08.010

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.08.010

1 reference

25 November 2017

1 reference